Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;50(6):2710-2719.
doi: 10.1007/s00261-024-04717-7. Epub 2024 Nov 27.

Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy

Joseph Lee  1 , Kamran Salari  2 , Sirisha Nandalur  3 , Chen Shen  2 , Sayf Al-Katib  2 , Lili Zhao  2 , Daniel Krauss  2 , Andrew Thompson  3 , Zachary Seymour  4 , Kiran Nandalur  2
Affiliations

Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy

Joseph Lee et al. Abdom Radiol (NY). 2025 Jun.

Abstract

Purpose: This study evaluates pretreatment prostate magnetic resonance imaging (MRI) metrics and clinical characteristics in predicting biochemical recurrence (BCR) after prostate radiotherapy (RT).

Methods: In this retrospective single institution study, we identified men in our prostate cancer database who underwent MRI within 6 months prior to completing definitive RT from May 2011 to February 2023. Central gland volume and peripheral zone volume were measured by a radiologist using manual segmentation, along with Prostate Imaging-Reporting and Data System (PI-RADS) score. The primary objective was to determine the association of central gland volume with biochemical recurrence per Phoenix criteria. Multivariable and inverse probability weighted (IPW) Cox proportional hazards regression models were constructed.

Results: A total of 373 men were included, with a median follow-up of 28 months. Thirteen (3.5%) were low risk, 97 (26%) favorable intermediate risk, 201 (53.9%) unfavorable intermediate risk, and 62 (16.6%) high risk. Fifty-four (14.5%) patients received conventionally fractionated RT, 105 (28.2%) moderately hypofractionated RT, 121 (32.4%) high-dose rate brachytherapy, and 93 (24.9%) stereotactic body RT. The 3- and 5-year rates of BCR were 7.8% and 18.3%, respectively. Higher central gland volume (per 5 cc) was associated with decreased risk of BCR (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: 0.50-0.94, p = 0.02) on the multivariable Cox model and IPW model (HR: 0.75, 95% CI: 0.65-0.87, p < 0.001). No significant association was seen with peripheral zone volume, PI-RADS score, or RT modality.

Conclusion: Increased central gland volume on pretreatment prostate MRI is independently associated with a lower risk of biochemical recurrence after definitive radiation for prostate cancer. Central gland volume may improve patient selection and oncologic risk stratification prior to offering RT.

Keywords: Biochemical recurrence; Central gland volume; Prostate MRI; Prostate cancer; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. National Cancer Institute. Cancer stat facts: prostate cancer. Available at: ( https://seer.cancer.gov/statfacts/html/prost.html ). Published 2023. Accessed March 16, 2024.
    1. Wang J, Xia HH, Zhang Y, et al. Trends in treatments for prostate cancer in the united states, 2010–2015. Am J Cancer Res 2021;11:2351–2368. - PubMed - PMC
    1. Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009;55:864–73. doi: https://doi.org/10.1016/j.eururo.2008.11.011 - DOI - PubMed
    1. Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013;10:49–54. doi: https://doi.org/10.1038/nrurol.2012.192 - DOI - PubMed
    1. Hong SK, Poon BY, Sjoberg DD, et al. Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology 2014;84:153–7. doi: https://doi.org/10.1016/j.urology.2014.04.006 - DOI - PubMed

Substances

LinkOut - more resources